Deals
Advent Said to Weigh Purchase of Swedish Biotech Firm Sobi
- Private equity firm reached out to Permira about joint bid
- Sobi’s market value approaches $7 billion as stock jumps
This article is for subscribers only.
Private equity firm Advent International is considering a potential purchase of drugmaker Swedish Orphan Biovitrum AB, people with knowledge of the matter said.
Advent is leading a consortium that’s exploring an acquisition of the Swedish biotech firm, the people said, asking not to be identified because the information is private. It has reached out to other buyout firms including Permira to gauge their interest in teaming up on the potential deal for Sobi, according to the people.